Navigation Links
Lawsuit Alleges Takeda Pharmaceutical Co., Maker of Diabetes Drug Actos, Didn’t Warn of the Drug’s Risks Soon Enough; Parker Waichman LLP Responds
Date:9/6/2013

New York, NY (PRWEB) September 06, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, notes that, according to a Sept. 4 Bloomberg report, during a trial over the diabetes drug Actos, a lawyer for the Plaintiff alleged Takeda Pharmaceutical Co. had failed to warn consumers about certain cancer risks related to the drug (An v. Nieberlein, 24-C12003565, Circuit Court for the City of Baltimore, State of Maryland).

Takeda officials knew by 2005 that studies had shown links between Actos and cancer and didn’t issue a warning until six years later, the lawyer alleged in opening arguments, according to the Bloomberg report.

The U.S. Food and Drug Administration (FDA), which approved Actos, has been warning of the risks of the drug since 2011. On June 15, 2011, the agency said that taking Actos for more than a year could significantly increase the risk of bladder cancer. The safety label on Actos was updated to address this risk.

“The FDA was among the first to determine the drug Actos can cause an elevated risk in bladder cancer among those who take it for around a year,” said Parker Waichman LLP. “At least now we seem to be on the same page about the potential dangers associated with this drug.”

Aside from the FDA, research studies from other groups provide additional support for the notion of a link between Actos and bladder cancer. The British Medical Journal published a study on May 31, 2012, that revealed Actos users were twice as likely to develop bladder cancer after two years. Then, on July 3, 2012, the Canadian Medical Association Journal reported that patients taking the medication were 22 percent more likely to get bladder cancer.

Parker Waichman LLP continues to offer free legal consultations to victims of injuries allegedly caused by Actos, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1-800-LAW-INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
1+ (800) LAW-INFO
1+ (800) 529-4636

Read the full story at http://www.prweb.com/releases/Actos_trial_Bloomberg/09/prweb11098139.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DePuy Knee Sleeve Lawsuits Help: Resource4thePeople Expands Recall Reviews to include both Knee and Hip Cases
2. Biomet Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order and Stipulation in Federal Biomet Hip Replacement Litigation
3. DePuy Pinnacle Lawsuit News: Claims Filed in Federal DePuy Pinnacle Hip Litigation Approach 5,000, Bernstein Liebhard LLP Reports
4. Mirena IUD Lawsuit Help: Resource4thePeople Reports Number of Consolidated Cases Increases as Litigation Advances
5. C8 Lawsuit Lawyers at Wright & Schulte LLC Applaud Scheduling of First Trials in Multidistrict Litigation Established for Federal DuPont C8 Lawsuits
6. Actos Lawsuit News: Bernstein Liebhard LLP Notes Start of Second Actos Bladder Cancer Trial in Maryland State Court
7. Da Vinci Surgery Lawsuit News: Bernstein Liebhard LLP Comments on New Research that Suggests Robotic Surgery Complications Underreported
8. DrugRisk News: Court Consolidates Januvia Lawsuits Alleging Cancer
9. Transvaginal Mesh Lawsuits Help: Resource4thePeople Reports Key Trials Scheduled in Consolidated Federal Cases as Number of Cases Increases
10. Biomet Hip Lawsuits News: Judge Denies Biomet Motion to Dismiss Lawsuit, Reports Rottenstein Law Group LLP
11. NuvaRing Lawsuit Filed by Alonso Krangle Alleges That Use of NuvaRing Caused a Louisiana Woman to Develop a Life-Threatening Blood Clot Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp ... in and around the greater Phoenix metropolitan region, is announcing a charity event ... mission of the Homeless Youth Connection is to promote community awareness of the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, ... residential and commercial clients in the northern Alabama and Georgia regions, is embarking ... Since 1977, Nobis Works has built a network of support and education facilities ...
(Date:12/7/2016)... ... December 07, 2016 , ... Students attending Envision’s ... unique opportunity to get hands-on experience in an emergency medical simulation, When Care ... to gain invaluable, real-life medical skills that are critical success in a future ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... the drug in their bodies, a researcher at the Icahn School of Medicine ... Research. , The study found that when young children are exposed to secondhand ...
(Date:12/7/2016)... PHILADELPHIA, PA (PRWEB) , ... December 07, 2016 ... ... story of a women growing up with a schizophrenic mother in a unique, ... social worker who specializes in treating trauma and addictive disorders at her private ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... YORK , December 8, 2016 ... focused on the research, distribution, and marketing of pharmaceutical ... affected by patent protection and expiration. Additionally, these firms ... Healthcare sector as a whole. Up for review this ... ), Synergy Pharmaceuticals Inc. (NASDAQ: SGYP ), ...
(Date:12/8/2016)... DES MOINES, Iowa , Dec. 8, 2016 ... STLT), a pharmaceutical company advancing technologies designed to ... the appointment of Chitra Edwin , Ph.D., ... and Compliance. Dr. Edwin will provide leadership for ... planning for regulatory approvals, preparation of regulatory submissions, ...
(Date:12/7/2016)... , Dec. 7, 2016 "Lantus (Insulin Glargine) Biosimilar Clinical Trial ... 37 biosimilar version of Lantus drug in clinical pipeline. Currently 5 biosimilar ... Japan , Kenya , ... , China , Slovakia , ... & 2 diabetes mellitus. The patent on Lantus expired in 2014. ...
Breaking Medicine Technology: